SRPT is expected to report earnings to fall -102% to -2 cents per share on May 01

A.I.dvisor
at Tickeron.com
04/30/24
Loading...
SRPT - Sarepta Therapeutics
Sarepta Therapeutics Earnings Graph
Q1'24
Est.
$-0.02
Q4'23
Beat
by $0.84
Q3'23
Beat
by $0.76
Q2'23
Beat
by $0.92
Q1'23
Missed
by $4.57
The last earnings report on December 31 showed earnings per share of 82 cents, beating the estimate of -2 cents. P/B Ratio (14.164) is normal, around the industry mean (10.220). P/E Ratio (0.000) is within average values for comparable stocks, (115.380). SRPT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.468). SRPT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (9.569) is also within normal values, averaging (237.012). With 1.04M shares outstanding, the current market capitalization sits at 12.17B.
View a ticker or compare two or three
SRPTDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of treatments for life-threatening illnesses and viruses

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
215 First Street
Phone
+1 617 274-4000
Employees
1314
Web
https://www.sarepta.com